SilkTech Biopharmaceuticals

SilkTech Biopharmaceuticals is a clinical-stage company that leverages the natural therapeutic properties of silk-derived proteins to develop an innovative biopharmaceutical product aimed at treating the signs and symptoms of dry eye disease (DED). It is estimated that more than 340 million people worldwide suffer from DED, with 15 million currently diagnosed in the United States and 40 million undiagnosed, presenting a significant treatment challenge for clinicians.